Skip to main content
 

Press Releases

April 12, 2017

• Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reversal of the Patent Trial and Appeals Board’s decision to terminate CRISPR/Cas9 interference
• In parallel, the companies and their licensors plan to pursue additional patents in the U.S. and worldwide covering the CRISPR/Cas9 technology and its use in cellular and non-cellular settings, including eukaryotic cells

February 15, 2017
 UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells

In the News

The Atlantic “WHAT’S NEXT?”: Hacking the Genome

October 6, 2016

Rachel Haurwitz, President and CEO of Caribou Biosciences, is interviewed by Ross Andersen, Senior Editor of The Atlantic, at the “WHAT’S NEXT?” summit. She discusses the impact of CRISPR for the scientific community, the big issues in gene editing, and the future of this technology for therapeutics and agriculture.

 

PBS: Editing Out Pesticides

August 3, 2016

This summer, more than a million tons of chardonnay grapes are plumping on manicured vineyards around the world. The grapes make one of the most popular white wines, but their juicy fruit and luscious leaves are also targets for diseases such as downy mildew, a stubborn fungus-like parasite.

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Vice President
Feinstein Kean Healthcare
(404) 836-2302
gregory.kelley@fkhealth.com